Our results linking diminished lung function and vasculopathy with severe fatigue in patients with SSc, inspired us to explore the possibility of Gal-9 elevation as a potential indicator of disease-associated damage accrual in both the UofA and CSRG cohorts. This evidence concerns the gene LGALS9 and systemic sclerosis.